share_log

新銳醫藥：主要交易 －收購目標公司16%已發行股本

NEW RAY MEDIC: MAJOR TRANSACTION -ACQUISITION OF 16% OF THE ISSUED SHARE CAPITALOF THE TARGET COMPANY

Hong Kong Stock Exchange ·  May 16 08:34
Summary by Moomoo AI
新銳醫藥國際控股有限公司（新锐医药）宣布於2024年5月16日與獨立第三方于文勇簽訂買賣協議，收購目標公司中國女媧醫藥集團股份有限公司16%的已發行股本，交易代價為17,280,000港元。該交易將使新銳醫藥進一步擴展其在中國的醫藥產品製造、銷售及分銷業務。根據上市規則，此次收購構成主要交易，需遵守通知、公佈及股東批准的規定。公司將於2024年6月21日或之前召開股東特別大會，並預期寄發相關通函。目標集團於2023年度的未經審核營業額為92,790千港元，除稅前溢利為9,763千港元。完成交易後，新銳醫藥將持有目標公司16%的股權。
新銳醫藥國際控股有限公司（新锐医药）宣布於2024年5月16日與獨立第三方于文勇簽訂買賣協議，收購目標公司中國女媧醫藥集團股份有限公司16%的已發行股本，交易代價為17,280,000港元。該交易將使新銳醫藥進一步擴展其在中國的醫藥產品製造、銷售及分銷業務。根據上市規則，此次收購構成主要交易，需遵守通知、公佈及股東批准的規定。公司將於2024年6月21日或之前召開股東特別大會，並預期寄發相關通函。目標集團於2023年度的未經審核營業額為92,790千港元，除稅前溢利為9,763千港元。完成交易後，新銳醫藥將持有目標公司16%的股權。
XINJIE PHARMACEUTICALS INTERNATIONAL HOLDINGS LIMITED (XIN PHARMACEUTICALS) ANNOUNCED ON 16 MAY 2024 AN AGREEMENT WITH AN INDEPENDENT THIRD PARTY YUEN YU WENYONG TO ACQUIRE 16% OF THE ISSUED SHARE CAPITAL OF TARGET COMPANY CHINA MEJIAN PHARMACEUTICAL GROUP CO., LTD. AT A PRICE OF HK$17,280,000. The transaction will enable Novi Pharmaceuticals to further expand its pharmaceutical product manufacturing, sales and distribution business in China. According to the Listing Rules, this acquisition constitutes a major transaction and is subject to notice, announcement and shareholder approval. The Company will hold an Extraordinary General Meeting on or before June 21, 2024 and is expected to send the relevant circular. Target Group had an unaudited revenue of HK$92,790 thousand in 2023 and a profit before tax of HK$9,763 thousand. Upon completion of the transaction, Novi Pharmaceuticals will hold a 16% stake in the target company.
XINJIE PHARMACEUTICALS INTERNATIONAL HOLDINGS LIMITED (XIN PHARMACEUTICALS) ANNOUNCED ON 16 MAY 2024 AN AGREEMENT WITH AN INDEPENDENT THIRD PARTY YUEN YU WENYONG TO ACQUIRE 16% OF THE ISSUED SHARE CAPITAL OF TARGET COMPANY CHINA MEJIAN PHARMACEUTICAL GROUP CO., LTD. AT A PRICE OF HK$17,280,000. The transaction will enable Novi Pharmaceuticals to further expand its pharmaceutical product manufacturing, sales and distribution business in China. According to the Listing Rules, this acquisition constitutes a major transaction and is subject to notice, announcement and shareholder approval. The Company will hold an Extraordinary General Meeting on or before June 21, 2024 and is expected to send the relevant circular. Target Group had an unaudited revenue of HK$92,790 thousand in 2023 and a profit before tax of HK$9,763 thousand. Upon completion of the transaction, Novi Pharmaceuticals will hold a 16% stake in the target company.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more